Compare Gilead Sciences, Inc. (GILD) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while Tripadvisor Inc Common Stock trades at $14.52 (market cap $1.70B). The key difference: Gilead Sciences, Inc. is far larger — about 96.2× Tripadvisor Inc Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| GILD | TRIP | |
|---|---|---|
Market Cap | $163.51B | $1.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $19.14 |
52-Week Low | $108.22 | $9.24 |
Enterprise Value | $178.05B | $1.82B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tripadvisor (TRIP) trades at $14.00, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but beat in Q3 2025, with revenue growing to $1.89B in 2025. Recent news highlights the $700M sale of TheFork to American Express, providing strategic focus and cash infusion.
Outlook remains cautious with analyst consensus at Hold (60.72%) and price target of $13.87 below current price. Key risks include competitive pressures and macroeconomic headwinds, while opportunities lie in travel recovery and TheFork sale proceeds. The stock faces near-term pressure but has long-term potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
